Ad disclosure
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Moderna, Inc. (NASDAQ:MRNA)
Stock Price:
$139.89
-2.92
(-2.04%)
Updated
Jun 30, 2022 02:45 PM GMT+0000
Featured app
Invest now
75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.
Overview
Financials
Statistics
Profile
Chart
| Market Cap | 55.64B |
|---|---|
| Revenue | 22.60B |
| Gross Profit | 19.16B |
| Shares Out | 397.76M |
| EPS (ttm) | 34.04 |
| PE Ratio | 3.8806 |
| Forward PE | 5.1123 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Jun 30 |
|---|---|
| Last Price | $139.89 |
| Previous Close | $142.81 |
| Change ($) | -2.92 |
| Change (%) | -2.04% |
| Day's Open | 143.15 |
| Day's Range | Market Closed |
| Day's Volume | 1.61M |
| 52 Week Range | 115.61 - 497.49 |
About
Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
1,300
CEO
Stephane Bancel
Address
200 Technology Sq
Cambridge
Massachusetts
02139-3578
Cambridge
Massachusetts
02139-3578
Phone
16177146500
Website
www.modernatx.com
Ticker Symbol
MRNA
Exchange
NASDAQ Stock Exchange
Reporting Currency
USD
Moderna, Inc. earnings reports (2020)
| Q3 2020 | Q2 2020 | Q1 2020 | Q1 2020 | |
|---|---|---|---|---|
| Actual EPS | -0.59 | -0.31 | -0.35 | -0.35 |
| Consensus EPS | -0.38 | -0.35 | -0.35 | -0.35 |
| Announce Time | BTO | BTO | BTO | BTO |
| Number of Estimates | 11 | 11 | 9 | 9 |
| EPS Surprise Dollar | -0.21 | 0.04 | 0 | 0 |
| EPS Report Date | 29-10-2020 | 05-08-2020 | 06-05-2020 | 06-05-2020 |
| Fiscal End Date | 30-09-2020 | 30-06-2020 | 30-03-2020 | 30-03-2020 |
| Year Ago | -0.37 | -0.41 | -0.4 | -0.4 |
| Year Ago % Change | -59.46% | 24.39% | 12.5% | 12.5% |
Moderna, Inc. earnings reports (2019)
| Q4 2019 | Q3 2019 | Q2 2019 | |
|---|---|---|---|
| Actual EPS | -0.37 | -0.37 | -0.41 |
| Consensus EPS | -0.42 | -0.44 | -0.45 |
| Announce Time | BTO | BTO | BTO |
| Number of Estimates | 8 | 7 | 6 |
| EPS Surprise Dollar | 0.05 | 0.07 | 0.04 |
| EPS Report Date | 26-02-2020 | 06-11-2019 | 06-08-2019 |
| Fiscal End Date | 31-12-2019 | 29-09-2019 | 29-06-2019 |
| Year Ago | -0.44 | -0.3 | N.A |
| Year Ago % Change | 15.91% | -23.33% | N.A |
Moderna, Inc. income statements (2020) (USD)
| October 2020 | September 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|---|
| Total Revenue | 157.91M | N.A | N.A | N.A | N.A |
| Cost of Revenue | 0 | N.A | N.A | N.A | N.A |
| Gross Profit | 157.91M | N.A | N.A | N.A | N.A |
| Research & Development | 344.49M | 344.49M | 144.26M | 107.69M | 107.69M |
| Selling General & Admin | 48.54M | 48.54M | 36.62M | 24.11M | 24.11M |
| Operating Expense | 393.03M | N.A | N.A | N.A | N.A |
| Operating Income | -235.12M | -235.12M | -122.13M | -130.86M | -130.86M |
| Other Income Expense Net | 0 | 2.35M | 5.56M | 6.70M | 6.70M |
| EBIT | -235.12M | -235.12M | -122.13M | -130.86M | -130.86M |
| Interest Income | -5.57M | N.A | 1.88M | 1.67M | 1.67M |
| Pretax Income | -232.77M | -232.77M | -116.57M | -124.16M | -124.16M |
| Income Tax | 864K | 864K | 148K | 66K | 66K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Net Income | -233.64M | -233.64M | -116.71M | -124.23M | -124.23M |
| Net Income Basic | -233.64M | -233.64M | -116.71M | -124.23M | -124.23M |
Moderna, Inc. income statements (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Total Revenue | N.A | N.A | N.A | N.A |
| Cost of Revenue | N.A | N.A | N.A | N.A |
| Gross Profit | N.A | N.A | N.A | N.A |
| Research & Development | 109.82M | 112.42M | 128.50M | 130.58M |
| Selling General & Admin | 25.86M | 28.19M | 21.02M | 19.96M |
| Operating Expense | N.A | N.A | N.A | N.A |
| Operating Income | -130.56M | -130.86M | -143.94M | -141.83M |
| Other Income Expense Net | 6.15M | 7.49M | 8.56M | 9.15M |
| EBIT | -130.56M | -130.86M | -143.94M | -141.83M |
| Interest Income | 2M | 1.54M | 1.54M | 1.53M |
| Pretax Income | -124.41M | -123.37M | -135.38M | -132.68M |
| Income Tax | -169K | -178K | -324K | -24K |
| Minority Interest | 0 | 0 | 0 | 0 |
| Net Income | -124.24M | -123.19M | -135.05M | -132.66M |
| Net Income Basic | -124.24M | -123.19M | -135.05M | -132.66M |
Moderna, Inc. income statements (2018) (USD)
| December 2018 | September 2018 | |
|---|---|---|
| Total Revenue | N.A | N.A |
| Cost of Revenue | N.A | N.A |
| Gross Profit | N.A | N.A |
| Research & Development | 150.43M | 109.05M |
| Selling General & Admin | 30.67M | 12.04M |
| Operating Expense | N.A | N.A |
| Operating Income | -153.03M | -85.82M |
| Other Income Expense Net | 11.77M | 5.49M |
| EBIT | -153.03M | -85.82M |
| Interest Income | 1.53M | N.A |
| Pretax Income | -141.26M | -80.33M |
| Income Tax | 168K | N.A |
| Minority Interest | 0 | 0 |
| Net Income | -141.43M | -80.33M |
| Net Income Basic | -144.1M | -87.82M |
Moderna, Inc. income statements (2017) (USD)
| December 2017 | September 2017 | |
|---|---|---|
| Total Revenue | N.A | N.A |
| Cost of Revenue | N.A | N.A |
| Gross Profit | N.A | N.A |
| Research & Development | 117.83M | 93.61M |
| Selling General & Admin | 9.99M | 11.60M |
| Operating Expense | N.A | N.A |
| Operating Income | -41.83M | -67.87M |
| Other Income Expense Net | 3.71M | 3.09M |
| EBIT | -41.83M | -67.87M |
| Interest Income | N.A | N.A |
| Pretax Income | -38.12M | -64.79M |
| Income Tax | -171K | -2K |
| Minority Interest | 0 | 0 |
| Net Income | -37.94M | -64.78M |
| Net Income Basic | -41.43M | -68.26M |
Moderna, Inc. balance sheet (2020) (USD)
| October 2020 | June 2020 | March 2020 | March 2020 | |
|---|---|---|---|---|
| Current Cash | 3.28B | 1.76B | 392.75M | 392.75M |
| Receivables | 213.45M | 33.36M | 7.30M | 7.30M |
| Inventory | 0 | N.A | N.A | N.A |
| Current Assets | 3.58B | 2.80B | 1.25B | 1.25B |
| Other Current Assets | 86.42M | 20.85M | 12.41M | 12.41M |
| Short Term Investments | 86.42M | 0.96B | 825.98M | 825.98M |
| Long Term Investments | 1.07B | 365.71M | 513.27M | 513.27M |
| Property/Plant Equipment | 276.91M | 321.99M | 302.60M | 302.60M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | 0 | N.A | N.A | N.A |
| Tangible Assets (Net) | 2.76B | 2.95B | 1.64B | 1.64B |
| Other Assets | 2.05M | 1.57M | 1.74M | 1.74M |
| Total Assets | 4.65B | 3.49B | 2.07B | 2.07B |
| Accounts Payable | 20.52M | 18.82M | 11.03M | 11.03M |
| Other Current Liabilities | 1.45B | 138.64M | 119.56M | 119.56M |
| Total Current Liabilities | 1.47B | 161.65M | 134.58M | 134.58M |
| Total Liabilities | 1.89B | 539.12M | 426.67M | 426.67M |
| Long Term Debt | 108.61M | 167.77M | 147.85M | 147.85M |
| Current Long Term Debt | 0 | N.A | N.A | N.A |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 4.73B | 393.28M | 370.10M | 370.10M |
| Treasury Stock | 0 | N.A | N.A | N.A |
| Retained Earnings | -1.97B | -1.74B | -1.62B | -1.62B |
| Capital Surplus | N.A | 4.68B | 3.27B | 3.27B |
| Shareholder Equity | 2.76B | 2.95B | 1.64B | 1.64B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Moderna, Inc. balance sheet (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Current Cash | 236.91M | 174.74M | 151.62M | 502.93M |
| Receivables | 5.37M | 8.22M | 4.52M | 6.61M |
| Inventory | N.A | N.A | N.A | N.A |
| Current Assets | 1.13B | 1.09B | 1.10B | 1.14B |
| Other Current Assets | 8.48M | 9.73M | 9.20M | 7.90M |
| Short Term Investments | 867.12M | 884.83M | 0.92B | 605.99M |
| Long Term Investments | 170.78M | 290.65M | 365.03M | 437.66M |
| Property/Plant Equipment | 287.91M | 203.69M | 208.51M | 213.46M |
| Good Will | N.A | N.A | N.A | N.A |
| Intangible Assets | N.A | N.A | N.A | N.A |
| Tangible Assets (Net) | 1.17B | 1.25B | 1.34B | 1.45B |
| Other Assets | 1.93M | 2.09M | 14.32M | 14.26M |
| Total Assets | 1.59B | 1.59B | 1.69B | 1.81B |
| Accounts Payable | 7.09M | 11.74M | 29.61M | 38.51M |
| Other Current Liabilities | 132.44M | 136.11M | 132.38M | 112.89M |
| Total Current Liabilities | 143.12M | 147.84M | 161.99M | 159.16M |
| Total Liabilities | 414.61M | 339.09M | 346.73M | 360.17M |
| Long Term Debt | 132.36M | 33.80M | 33.59M | 33.38M |
| Current Long Term Debt | N.A | N.A | N.A | 7.76M |
| Minority Interest | 0 | 0 | 0 | 0 |
| Common Stock | 336.54M | 332.49M | 329.96M | 328.85M |
| Treasury Stock | N.A | N.A | N.A | N.A |
| Retained Earnings | -1.5B | -1.37B | -1.25B | -1.11B |
| Capital Surplus | 2.67B | 2.62B | 2.58B | 2.56B |
| Shareholder Equity | 1.17B | 1.25B | 1.34B | 1.45B |
| Other Liabilities | N.A | N.A | N.A | N.A |
Moderna, Inc. balance sheet (2018) (USD)
| December 2018 | September 2018 | |
|---|---|---|
| Current Cash | 658.96M | 167.89M |
| Receivables | 12.59M | 11.56M |
| Inventory | N.A | N.A |
| Current Assets | 1.56B | 1.12B |
| Other Current Assets | 10.40M | 27.32M |
| Short Term Investments | 863.06M | 0.91B |
| Long Term Investments | 175.62M | 161.89M |
| Property/Plant Equipment | 211.98M | 206.46M |
| Good Will | N.A | N.A |
| Intangible Assets | N.A | N.A |
| Tangible Assets (Net) | 1.53B | 1.08B |
| Other Assets | 11.54M | 2.87M |
| Total Assets | 1.96B | 1.49B |
| Accounts Payable | 31.21M | 24.36M |
| Other Current Liabilities | 181.09M | 162.06M |
| Total Current Liabilities | 222.80M | 186.42M |
| Total Liabilities | 431.91M | 412.73M |
| Long Term Debt | 33.49M | 26.89M |
| Current Long Term Debt | 10.50M | N.A |
| Minority Interest | 0 | 0 |
| Common Stock | 328.80M | 332.89M |
| Treasury Stock | N.A | N.A |
| Retained Earnings | -1.01B | -865.2M |
| Capital Surplus | 2.54B | 108.98M |
| Shareholder Equity | 1.53B | 1.08B |
| Other Liabilities | N.A | N.A |
Moderna, Inc. balance sheet (2017) (USD)
| December 2017 | |
|---|---|
| Current Cash | 135.81M |
| Receivables | 13.42M |
| Inventory | N.A |
| Current Assets | 783.22M |
| Other Current Assets | 9.59M |
| Short Term Investments | 621.17M |
| Long Term Investments | 157.65M |
| Property/Plant Equipment | 139.03M |
| Good Will | N.A |
| Intangible Assets | N.A |
| Tangible Assets (Net) | 625.30M |
| Other Assets | 4.59M |
| Total Assets | 1.08B |
| Accounts Payable | 20.73M |
| Other Current Liabilities | 170.74M |
| Total Current Liabilities | 191.46M |
| Total Liabilities | 459.19M |
| Long Term Debt | 15.69M |
| Current Long Term Debt | N.A |
| Minority Interest | 0 |
| Common Stock | 332.89M |
| Treasury Stock | N.A |
| Retained Earnings | -621.89M |
| Capital Surplus | 71.67M |
| Shareholder Equity | 625.30M |
| Other Liabilities | N.A |
Moderna, Inc. cash flow (2020) (USD)
| October 2020 | June 2020 | March 2020 | |
|---|---|---|---|
| Net Income | -233.64M | -116.71M | -124.23M |
| Depreciation | 23.55M | 7.60M | 7.45M |
| Changes in Receivables | 155.60M | -26.06M | -1.93M |
| Changes in Inventories | 0 | N.A | N.A |
| Cash Change | 559.29M | 1.37B | 155.84M |
| Cash Flow | -762.68M | -22.64M | -121.44M |
| Capital Expenditures | -44.15M | -18.63M | -6.22M |
| Investments | N.A | 31.11M | -309.8M |
| Investing Activity (other) | N.A | N.A | N.A |
| Total Investing Cash Flows | -1.48B | 12.48M | -316.02M |
| Dividends Paid | N.A | N.A | N.A |
| Net Borrowings | -3.25B | -1.19M | 15.24M |
| Other Financing Cash Flows | N.A | -241K | 241K |
| Cash Flow Financing | 1.99B | 1.38B | 593.30M |
| Exchange Rate Effect | N.A | N.A | N.A |
Moderna, Inc. cash flow (2019) (USD)
| December 2019 | September 2019 | June 2019 | March 2019 | |
|---|---|---|---|---|
| Net Income | -124.24M | -123.19M | -135.05M | -132.66M |
| Depreciation | 8.94M | 7.27M | 7.49M | 7.33M |
| Changes in Receivables | 2.85M | -3.7M | 2.09M | 5.97M |
| Changes in Inventories | N.A | N.A | N.A | N.A |
| Cash Change | 62.17M | 22.09M | -351.31M | -155.73M |
| Cash Flow | -107.45M | -107.05M | -112.22M | -143.93M |
| Capital Expenditures | -6.66M | -6.71M | -10.59M | -7.6M |
| Investments | 137.01M | 120.08M | -236.32M | -4.16M |
| Investing Activity (other) | N.A | N.A | N.A | N.A |
| Total Investing Cash Flows | 130.35M | 113.37M | -246.9M | -11.76M |
| Dividends Paid | N.A | N.A | N.A | N.A |
| Net Borrowings | 8.66M | 3.89M | 204K | -105K |
| Other Financing Cash Flows | N.A | -3.68M | 3.68M | N.A |
| Cash Flow Financing | 39.27M | 15.77M | 7.81M | -48K |
| Exchange Rate Effect | N.A | N.A | N.A | N.A |
Moderna, Inc. cash flow (2018) (USD)
| December 2018 | September 2018 | |
|---|---|---|
| Net Income | -141.43M | -80.33M |
| Depreciation | 7.35M | N.A |
| Changes in Receivables | -1.03M | 1.86M |
| Changes in Inventories | N.A | N.A |
| Cash Change | 491.30M | N.A |
| Cash Flow | -91.02M | N.A |
| Capital Expenditures | -13.64M | N.A |
| Investments | 20.05M | N.A |
| Investing Activity (other) | N.A | N.A |
| Total Investing Cash Flows | 6.41M | N.A |
| Dividends Paid | N.A | N.A |
| Net Borrowings | 187K | N.A |
| Other Financing Cash Flows | 11.64M | N.A |
| Cash Flow Financing | 575.92M | N.A |
| Exchange Rate Effect | N.A | N.A |
Moderna, Inc. cash flow (2017) (USD)
| December 2017 | |
|---|---|
| Net Income | -37.94M |
| Depreciation | 5.92M |
| Changes in Receivables | N.A |
| Changes in Inventories | N.A |
| Cash Change | 11.41M |
| Cash Flow | -102.93M |
| Capital Expenditures | -11.96M |
| Investments | 124.76M |
| Investing Activity (other) | N.A |
| Total Investing Cash Flows | 112.80M |
| Dividends Paid | N.A |
| Net Borrowings | 1.44M |
| Other Financing Cash Flows | N.A |
| Cash Flow Financing | 1.54M |
| Exchange Rate Effect | N.A |
Moderna, Inc. dividends (USD)
Total Valuation
Moderna Inc has a market cap or net worth of $55.64 billion. The enterprise value is $47.50 billion.
Market Cap
55.64B
Enterprise Value
47.50B
Important Dates
Earnings Date
Aug 4, 2022
Ex-Dividend Date
n.a
Share Statistics
Moderna Inc has 397.76 million shares outstanding.
Shares Outstanding
397.76M
Float
n.a
Valuation Ratios
The trailing PE ratio is 3.8806 and the forward PE ratio is 5.1123. Moderna Inc's PEG ratio is 0.0018.
PE Ratio
3.8806
Forward PE
5.1123
PS Ratio
2.5100
PB Ratio
3.3300
PEG Ratio
0.0018
Stock Price Statistics
The stock price has decreased by -0.4377%. The beta is 0.0000, so Moderna Inc's price volatility has been lower than the market average.
Beta (1Y)
0.0000
52-Week Price Change
-0.4377%
50-Day Moving Average
136.65
200-Day Moving Average
166.82
Average Volume (30 Days)
5.43M
Income Statement
In the last 12 months, Moderna Inc had revenue of $22.60 billion and earned $19.16 billion in profits. Earnings per share was $34.04.
Revenue
22.60B
Gross Profit
19.16B
EBITDA
16.55B
Earnings per Share
34.04
About
Country
United States
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Employees
1,300
CEO
Stephane Bancel
Address
200 Technology Sq
Cambridge
Massachusetts
02139-3578
Cambridge
Massachusetts
02139-3578
Phone
16177146500
Website
www.modernatx.com
Ticker Symbol
MRNA
Reporting Currency
USD
Company Description
Moderna, Inc is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based on messenger RNA..